Smallcaps.us provided their subscribers with an update regarding their four featured companies: HemoBioTech Inc. (OTCBB: HMBT), Playlogic Entertainment (OTCBB: PLGC), Remedent Inc. (OTCBB: REMI) and AML Communications (OTCBB: AMLJ)
HemoBioTech announced last week that it has promoted Saraswathy Swaminathan to the position of Manager of Foreign Clinical Affairs. The company is developing what could be the world’s first viable substitute for human blood.
Playlogic Entertainment announced that it has signed a worldwide 3-year license, with a 2-year extension, on all gaming platforms for its popular franchise, “Dragon Hunters with Futurikon.” The upcoming movie based on the game, accompanied by media attention, could significantly impact the number of sales.
AML Communications is expected to release financial results for the first quarter of FY 2008. The company has received a couple large orders throughout the first quarter which are valued at a combined amount of approximately $2.4 million.
Remedent Inc. is believed by SmallCAPS.us to be undervalued because of its ability to attract a select group of distributors, has a product which is likely to begin a revolution, is in a strong market sector, and has a skilled management team.
Let us hear your thoughts below: